Thin endometrium
Conditions
Interventions
Treatment group:Umbilical cord blood mononuclear cells gel perfusion
Control group:Conventional treatment
Sponsors
Reproductive Hospital Affiliated to Shandong University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Voluntary signing of informed consent form; 2.Married women aged 20-43 years old; 3.Body Mass Index (BMI) 18-30kg/m^2; 4.Indications for in vitro fertilization; 5.After using artificial cycles, endometrial stimulation, sildenafil, aspirin, ovulation induction regimens, and other methods for at least three months, the thickness of the endometrium on ovulation or progesterone days remains <= 7mm; 6.At present, no obvious abnormalities have been found during hysteroscopy examination.
Exclusion criteria
Exclusion criteria: 1.Participants with recurrent miscarriage who have had at least 3 natural miscarriages in the past; 2. Select individuals who have participated in other clinical trials within the previous 2 months and have used the investigational drug; 3.Other uterine infusion treatments, such as granulocyte colony-stimulating factor, bone marrow mesenchymal stem cells, platelet enriched plasma, etc., have been performed within one month prior to screening; 4.Screening for abnormal cervical examination results with clinical significance within the previous 2 months; 5. Currently, there are participants with acute infections of the urinary and reproductive systems 6. According to the researcher's judgment, individuals with major systemic diseases, major endocrine or metabolic abnormalities that are not suitable for participation in this study 7.According to the researchers' judgment, there were clinically significant participants in the human group who had abnormalities in the uterus (such as submucosal uterine fibroids, intramural uterine fibroids larger than 3cm or smaller than 3cm but affecting the shape of the uterine cavity, untreated endometrial polyps, uterine adhesions, uterine effusion, uterine malformations, ASR stage II-IV endometriosis, adenomyosis), ovaries (ovarian cysts>4cm), or adnexa (such as hydrosalpinx); 8.Participants with unexplained abnormal uterine bleeding; 9.Individuals with a history of malignant tumors in the ovaries, breasts, uterus, hypothalamus, pituitary gland, etc; 10.Known past or current thromboembolic disease; 11.Suffering from known severe mental illness or unable to understand the purpose, methods, etc. of this clinical trial; And those who do not comply with research procedures; 12.Regarding the application of GnRH-a r-hFSHhCG Individuals with contraindications or a history of allergies to progesterone drugs; 1.Individuals with bad habits such as alcoholism, smoking, drug use, and substance abuse; 14.Exposure to teratogenic doses of radiation, toxins, and drugs and being in the active period; 15.HIV or syphilis positive; 16.Those who experience fever on the day of infusion; 17.Other reasons why researchers believe it is not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| liver birth rate;Embryo implantation rate;Endometrial thickness; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Continuous pregnancy rate; | — |
Countries
China
Contacts
Public ContactLei Yan
Hospital for Reproductive Medicine Affiliated to Shandong University
Outcome results
None listed